Cepton (NASDAQ:CPTN) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 30.77 percent increase over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $2.56 million which beat the analyst consensus estimate of $2.17 million by 17.93 percent. This is a 185.92 percent increase over sales of $895.00 thousand the same period last year.
Lucid Diagnostics Announces Peer-Reviewed Publication Of Results From Three Clinical Utility Studies; Studies Demonstrate Real-World Clinical Utility Of EsoGuard Testing To Detect Esophageal Precancer
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)))) ( "PAVmed"),
